Trials with AMT2003
Every colorectal cancer trial that includes this drug. Those looking for patients come first.
Showing 1–2 of 2
NCT00405561
The purpose of the study is to evaluate efficacy and safety of AMT2003 in cancer patients with advanced colorectal carcinoma. The primary endpoint is progression free survival rate at 18 weeks after registration
NCT00332280
The purpose of the study is to evaluate the efficacy and the safety of AMT2003 in cancer patients with advanced disease. The primary evaluation criterion is clinical benefit response.